Nattokinase
Research Reliability -
A fibrinolytic enzyme from fermented soy that supports healthy blood flow, circulation, and cardiovascular protection.
Appetite
Mood
Sleep
Nattokinase
Description
Nattokinase is a serine protease enzyme extracted from natto (fermented soybeans) with fibrinolytic activity, meaning it directly breaks down fibrin, the protein involved in blood clot formation. This action supports healthy blood viscosity, reduces the risk of excessive clotting, and promotes better circulation throughout the cardiovascular system. Research suggests it may help lower blood pressure modestly and support arterial health over time. It is often used as a natural complement to anticoagulant strategies, though individuals on blood-thinning medications should consult a physician before use.
Effects
First days
no sensation
Days to 2 weeks
supports blood flow and pressure quietly
Ongoing
circulatory maintenance
How it Feels
There is nothing to feel here; the effect is on blood viscosity and flow. Take it seriously as a blood-thinning agent: it should not be combined with anticoagulants or taken before surgery. Value is mechanistic, not experiential.
Usage
Entry Dose
50mg (2000 FU)
Standard Dose
100mg (4000 FU)
Max Dose
200mg (8000 FU)
Onset
Days–2 weeks (fibrinolytic)
Combinations
Pairs well with
Synergistic
Serrapeptase — complementary fibrinolytic enzymes targeting different clot proteins
Omega-3 — both have antiplatelet and blood-flow supporting properties
Ginkgo biloba — combined circulation support via fibrinolytic and vasodilatory pathways
Avoid combining
Contraindicated
Warfarin / blood thinners — nattokinase is fibrinolytic; serious additive bleeding risk
Aspirin / NSAIDs — antiplatelet effects stack; avoid before surgery or injury risk periods
Biomarkers to Track
Subjective
(Daily)
Leg heaviness or swelling
Cardiovascular endurance feel
Brain fog frequency (1–10)
Objective
(Quarterly)
D-dimer (clotting activity marker)
Blood pressure (resting)
Fibrinogen level
Acts as a genuine blood thinner, so bleeding risk is the real concern.
Anyone on anticoagulants or antiplatelets, with a bleeding disorder, or facing surgery.
Stacking it with other blood thinners, and continuing it before a procedure.
Preliminary (limited / small human data)
Evidence for blood-clot and blood-pressure claims comes from small, short-duration studies; caution with concurrent blood thinners.
Kurosawa Y et al. (2015). Scientific Reports. Human study (nattokinase and fibrinolytic activity). PMID: 26521833.